Erschienen in:
17.02.2021 | EDITORIAL
The Question That Doesn’t Seem to Go Away: Cancer Risk of Anti-TNF Therapy
verfasst von:
Oren Ledder
Erschienen in:
Digestive Diseases and Sciences
|
Ausgabe 1/2022
Einloggen, um Zugang zu erhalten
Excerpt
Anti-tumor necrosis factor (TNF) therapy has revolutionized the treatment of inflammatory bowel disease (IBD) over the past two decades; for much of this period, the unresolved question of the potential cancer risk of this class of drug has been overshadowed by its therapeutic successes. Pediatric-onset IBD per se is associated with an increased risk of cancer overall, primarily of skin, lymphoid, and gastrointestinal origin according to large population studies [
1,
2]. In these, the risk estimates were similar regardless of exposure to corticosteroids, thiopurines, and/or anti-TNF therapy. …